Sermorelin: The Time-Tested GHRH Standard Sermorelin was the first growth hormone-releasing hormone (GHRH) analog to gain widespread clinical recognition
Product Specifications Compound: CJC-1295 with DAC Class: Synthetic GHRH analog with albumin-binding modification Origin: Modified GHRH (1-29) analog with N-terminal Drug Affinity Complex Molecular Weight: ~3647 Da Form: Lyophilized powder Vial Size: 5mg in 3mL glass vial Purity: 99%+ verified by HPLC and mass spectrometry (See COAs) Research Background CJC-1295 with DAC has been investigated in research literature across several scientific contexts: GHRH receptor pharmacology investigations into receptor binding kinetics, signal transduction, and cellular response mechanisms in pituitary cell models Albumin-binding peptide research studies examining how covalent serum albumin binding via maleimidopropionic acid modification affects peptide half-life, distribution, and stability properties Peptide half-life engineering analytical chemistry research on extended-duration peptide analogs and the structural modifications that enable prolonged biological activity Comparative GHRH analog research studies positioning CJC-1295 with DAC alongside other modified GHRH peptides (including Sermorelin and Tesamorelin) in cellular research contexts Structure-activity relationships peptide chemistry research on how DAC modification affects receptor binding affinity compared to non-modified GHRH analogs Cellular signaling pathway research investigations into GHRH receptor activation and downstream cellular signaling cascades CJC-1295 with DAC was originally developed by ConjuChem Biotechnologies as part of their broader Drug Affinity Complex peptide research platform, which utilized albumin-binding chemistry to extend peptide half-life across multiple research compound development programs
Because of this, retatrutide gives a wider way to help with weight loss and weight management
Many popular peptides appear on FDA safety-risk lists for compounding contexts
Who Is a Candidate for CJC-1295/Ipamorelin Therapy at Perfect B in Doral CJC-1295/Ipamorelin is appropriate for adults aged 30 and above with good baseline health, realistic expectations about the 8-12 week timeline for visible results, commitment to 5-6 day/week injection adherence, and access to baseline labs before starting
